Your browser doesn't support javascript.
COVID-19: From the Molecular Mechanisms to Treatment
Tanaffos ; 21(2):113-131, 2022.
Artículo en Inglés | EMBASE | ID: covidwho-2261787
ABSTRACT
The 2019 novel coronavirus (SARS-CoV-2) causes severe pneumonia called COVID-19 and leads to severe acute respiratory syndrome with a high mortality rate. The SARS-CoV-2 virus in the human body leads to jumpstarting immune reactions and multi-organ inflammation, which has poorer outcomes in the presence of predisposing conditions, including hypertension, dyslipidemia, dysglycemia, abnormal adiposity, and even endothelial dysfunction via biomolecular mechanisms. In addition, leucopenia, hypoxemia, and high levels of both cytokines and chemokines in the acute phase of this disease, as well as some abnormalities in chest CT images, were reported in most patients. The spike protein in SARS-CoV-2, the primary cell surface protein, helps the virus anchor and enter the human host cells. Additionally, new mutations have mainly happened for spike protein, which has promoted the infection's transmissibility and severity, which may influence manufactured vaccines' efficacy. The exact mechanisms of the pathogenesis, besides molecular aspects of COVID-19 related to the disease stages, are not well known. The altered molecular functions in the case of immune responses, including T CD4+, CD8+, and NK cells, besides the overactivity in other components and outstanding factors in cytokines like interleukin-2, were involved in severe cases of SARS-CoV-2. Accordingly, it is highly needed to identify the SARS-CoV-2 bio-molecular characteristics to help identify the pathogenesis of COVID-19. This study aimed to investigate the bio-molecular aspects of SARS-CoV-2 infection, focusing on novel SARS-CoV-2 variants and their effects on vaccine efficacy.Copyright © 2022 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran.
Palabras clave
covid-19, Molecular Mechanisms, SARS-CoV-2, Treatment, adult respiratory distress syndrome, clustered regularly interspaced short palindromic repeat, computer assisted tomography, coronavirus disease 2019/dt [Drug Therapy], disease severity, endocytosis, human, immunofluorescence assay, lymphocytopenia, matrix assisted laser desorption ionization time of flight mass spectrometry, nonhuman, pathophysiology, reverse transcription loop mediated isothermal amplification, review, Severe acute respiratory syndrome coronavirus 2, unindexed sequence, virus detection, virus transmission, atazanavir/dt [Drug Therapy], azithromycin/dt [Drug Therapy], baricitinib/dt [Drug Therapy], beclabuvir/dt [Drug Therapy], boceprevir/dt [Drug Therapy], camostat mesilate/dt [Drug Therapy], carfilzomib/dt [Drug Therapy], chloroquine/dt [Drug Therapy], ciclesonide/dt [Drug Therapy], cobicistat/dt [Drug Therapy], darunavir/dt [Drug Therapy], elbasvir/dt [Drug Therapy], eravacycline/dt [Drug Therapy], favipiravir/dt [Drug Therapy], grazoprevir/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], indinavir/dt [Drug Therapy], interferon/dt [Drug Therapy], lithium/dt [Drug Therapy], lopinavir plus ritonavir/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nelfinavir/dt [Drug Therapy], nitazoxanide/dt [Drug Therapy], oseltamivir/dt [Drug Therapy], polypeptide antibiotic agent/dt [Drug Therapy], remdesivir/dt [Drug Therapy], ribavirin/dt [Drug Therapy], saquinavir/dt [Drug Therapy], sorafenib/dt [Drug Therapy], streptomycin/dt [Drug Therapy], telaprevir/dt [Drug Therapy], thalidomide/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], umifenovir/dt [Drug Therapy], valrubicin/dt [Drug Therapy]
Buscar en Google
Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Idioma: Inglés Revista: Tanaffos Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Buscar en Google
Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Idioma: Inglés Revista: Tanaffos Año: 2022 Tipo del documento: Artículo